Welcome to the ePoster Viewing Panel of AICOG 2025

Incisional site scar metastasis from cancer cervix is extremely rare with an incidence 0.1-2 %. Cutaneous recurrence is associated with poor prognosis and there are no definite guidelines for management of these patients. Treatment modalities include- wide local excision, radiotherapy and chemotherapy. We present a case of a patient who underwent radical hysterectomy at a private hospital for ca cervix stage IB2 (DOS 22/5/21) and then referred at KSSCI for adjuvant treatment. Patient received EBRT and ICRT (DOC 2/9/21) On follow up visits,in Feb 2022 small pinpoint growth was seen at vaginal vault, LBC was suggestive of ASCUS with HPV 16 DNA positive and biopsy was suggestive of radiation induced changes. CECT showed an ill-defined heterogeneously enhancing soft tissue lesion 3x2.3x2.7 cm in anterior wall at scar site. The lesion was infiltrating underlying mesentry causing adjacent fat stranding. Patient was advised USG guided core biopsy from mass but she defaulted. Patient returned in July 2022 with a 10 x 8 cm size hard fixed per abdomen, FNAC from which was suggestive of metastasis from squamous cell carcinoma. Patient was offered palliative chemotherapy and wound dressings Though abdominal scar metastatic recurrence in cancer cervix is extremely rare and associated with poor prognosis. The treatment is mainly palliative in these cases due to the paucity of evidence and scanty number of reported cases no definite guidelines for the treatment of skin recurrences are present. The main treatment modalities are- surgical wide excision of lesion, radiotherapy and chemotherapy. Protective measures that can be undertaken during surgery to reduce the risk of recurrence- en block resection of the tumor, avoid excessive manipulation of tissues, lavage of the peritoneal cavity with heparin, providone iodine, normal saline post tumor resection.